2024
Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021
Kwon J, Pelletiers W, Peña J, van Duin D, Ledbetter L, Baum K, Ruffin F, Knisely J, Bizzell E, Fowler V, Chambers H, Pettigrew M. Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021. Clinical Infectious Diseases 2024, 79: 141-147. PMID: 38306502, PMCID: PMC11259209, DOI: 10.1093/cid/ciae049.Peer-Reviewed Original ResearchMethicillin-resistant S. aureusRandomized controlled trialsPhase 2/3 trialsPhase 4 trialIncidence of methicillin-resistant S. aureusTreat Staphylococcus aureus infectionsStaphylococcus aureus infectionStandard of carePercentage of study participantsIncidence ratiosClinical trialsEthnicity of participantsControlled trialsStandardized reporting methodsBlack participantsStudy sizeInfectionDisease populationTrialsStudy participantsAntibacterial agentsIncreased recruitmentIndustry sponsorshipEthnicity dataSex
2023
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review
Doernberg S, Arias C, Altman D, Babiker A, Boucher H, Creech C, Cosgrove S, Evans S, Fowler V, Fritz S, Hamasaki T, Kelly B, Leal S, Liu C, Lodise T, Miller L, Munita J, Murray B, Pettigrew M, Ruffin F, Scheetz M, Shopsin B, Tran T, Turner N, Williams D, Zaharoff S, Holland T, Patel R, King H, Kinamon T, Dai W, Geres H, Deckard N, Schuler C, Bunn I, Sharma S, Wickward C, Waller J, Wilson H, Mehigan M, Ghazaryan V, Raterman E, Samuel T, Lee M. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review. Clinical Infectious Diseases 2023, 77: s295-s304. PMID: 37843115, PMCID: PMC10578051, DOI: 10.1093/cid/ciad565.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupMRSA bloodstream infectionsMethicillin-resistant Staphylococcus aureusBloodstream infectionsClinical trialsPediatric community-acquired pneumoniaInfection researchEnterococcal bloodstream infectionsOptimal vancomycin dosingOptimization of dosingRole of dalbavancinCommunity-acquired pneumoniaShort-course therapyInterventional clinical trialsVancomycin-resistant enterococciVancomycin dosingPositive infectionsNovel agentsLife measuresTreat infectionsClinical practiceNarrative reviewInfectionPositive bacteriaStaphylococcus aureus
2013
Panel 6: Vaccines
Pelton SI, Pettigrew MM, Barenkamp SJ, Godfroid F, Grijalva CG, Leach A, Patel J, Murphy TF, Selak S, Bakaletz LO. Panel 6: Vaccines. Otolaryngology 2013, 148: e90-e101. PMID: 23536534, PMCID: PMC4029613, DOI: 10.1177/0194599812466535.Peer-Reviewed Original ResearchConceptsAcute otitis mediaPneumococcal conjugate vaccineOtitis mediaDevelopment of correlatesCandidate antigensAnimal modelsClinical efficacy trialsEffectiveness of vaccinesBurden of diseaseNontypeable Haemophilus influenzaeHuman clinical trialsOtitis pathogensConjugate vaccineVaccine strategiesPneumococcal serotypesClinical trialsMoraxella catarrhalisAdditional serotypesNew adjuvantsEfficacy trialsObservational studyFrequent recurrenceChild healthVaccine antigensMore antigens